Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $224.3 million offering of common stock of Constellation Pharmaceuticals, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “CNST.”

Based in Cambridge, Massachusetts, Constellation is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Cameron C. Lewis and Johnathan M. Nixon. Partner David R. Bauer and associate Christopher C. Woller provided intellectual property and technology advice. Partner William A. Curran and associate Alexander J. Hendin provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post